


Sheet 1 of 1

| FORM PTO-14 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO.: OC01626K | | APPLICATION NO.: 10/666,424 | |
|---|----|--|------------|--|-----------------------------------|---------------------------------------|-------------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT: Kamil Paruch et al. | | | |
| (Use several sheets if necessary) | | | | FILING DATE: 9/19/2003 | | GROUP: | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| | AL | EP 0 778 277 | 06/11/1997 | EPO | | | |
| | AM | WO 02/06286 | 01/24/2002 | PCT | | | |
| | AN | WO 88/04298 | 06/16/1988 | PCT | | | |
| | AO | | | | | | |
| | AP | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AQ | Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224 : 771-785. | | | | | |
| | AR | Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16 (9): 2986-2999. | | | | | |
| | AS | Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243 : 527-536. | | | | | |
| | AT | Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57 : 3375-3380. | | | | | |
| | AO | Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47 (7): 928-938. | | | | | |
| | AV | Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines", <i>Chem. Pharm. Bull.</i> (1962), 10 : 620-626. | | | | | |
| EXAMINER | | | | | DATE CONSIDERED 6/20/06 | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Sheet 1 of 2

| | | | | | | | |
|---|----|-------------------------|-------------------|--|-------|---------------------------------------|-------------------------------|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | ATTY. DOCKET NO.: OC01626K | | APPLICATION NO.: 10/666,424 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT: Kamil Paruch et al. | | | |
| <i>(Use several sheets if necessary)</i> | | | | FILING DATE: 09/19/2003 | | GROUP: | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| | AL | WO 2002 060492 A | 08/08/2002 | WIPO | | | |
| | AM | | | | | | |
| | AN | | | | | | |
| | AO | | | | | | |
| | AP | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AQ | | | | | | |
| | AR | | | | | | |
| | AS | | | | | | |
| | AT | | | | | | |
| | AU | | | | | | |
| | AV | | | | | | |
| EXAMINER  | | | | DATE CONSIDERED 10/20/06 | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Sheet 2 of 2

| | | | | | | | |
|--|----|---|------------|--|-------|---------------------------------------|-------------------------------|
| FORM PTO-600 PATENT & TRADEMARK OFFICE | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO.: OC01626K | | APPLICATION NO.: 10/666,424 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT: Kamil Paruch et al. | | | |
| | | | | FILING DATE: 09/19/2003 | | GROUP: | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| | AW | | | | | | |
| | AX | | | | | | |
| | AY | | | | | | |
| | AZ | | | | | | |
| | BA | | | | | | |
| | BB | | | | | | |
| | BC | | | | | | |
| | BD | | | | | | |
| | BE | | | | | | |
| | BF | | | | | | |
| | BG | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| | BH | WO 02/10162 | 02/07/2002 | WIPO | | | |
| | BI | | | | | | |
| | BJ | | | | | | |
| | BK | | | | | | |
| | BL | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | BM | A. Sanderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>J. Clin. Oncology</i> , 16 : 2986-2999 (1998). | | | | | |
| | BN | J. Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem.</i> , 224 : 771-786 (1994). | | | | | |
| | BO | I. Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", <i>Eur. J. Biochem.</i> , 243 : 527-536 (1997). | | | | | |
| | BP | K. S. Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>J. Medicinal Chemistry</i> , 45 : 3905-3927 (2002) | | | | | |
| | BQ | | | | | | |
| | BR | | | | | | |
| EXAMINER | | | | DATE CONSIDERED 6/20/06 | | | |
| *EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
OC01626KAPPLICATION NO.:
10/666,424**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**APPLICANT:
Kamil Paruch et al.*(Use several sheets if necessary)*FILING DATE:
09/19/2004

GROUP:

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------------|------|------|-------|---------------|-------------------------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION | |
|--|----|---------------------|-------------------|-------------|-------|---------------|-------------|----|
| | | | | | | | YES | NO |
| | AL | WO 03/089434 | 10/30/2003 | WIPO | | | | |
| | AM | | | | | | | |
| | AN | | | | | | | |
| | AO | | | | | | | |
| | AP | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|--|
| | AQ | |
| | AR | |
| | AS | |
| | AT | |
| | AU | |
| | AV | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.